IT8547624A0 - Ceppi batterici particolarmente utili per la produzione di vaccini per il trattamento di malattie intestinali e simili e metodo di ingegneria genetica per la produzione dei detti vaccini - Google Patents

Ceppi batterici particolarmente utili per la produzione di vaccini per il trattamento di malattie intestinali e simili e metodo di ingegneria genetica per la produzione dei detti vaccini

Info

Publication number
IT8547624A0
IT8547624A0 IT8547624A IT4762485A IT8547624A0 IT 8547624 A0 IT8547624 A0 IT 8547624A0 IT 8547624 A IT8547624 A IT 8547624A IT 4762485 A IT4762485 A IT 4762485A IT 8547624 A0 IT8547624 A0 IT 8547624A0
Authority
IT
Italy
Prior art keywords
vaccines
production
intestinal
treatment
particularly useful
Prior art date
Application number
IT8547624A
Other languages
English (en)
Other versions
IT1217303B (it
Inventor
Paul A Manning
Reeves Peter Richard
Rowley Derrick
Original Assignee
Enterovax Res Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enterovax Res Pty Ltd filed Critical Enterovax Res Pty Ltd
Publication of IT8547624A0 publication Critical patent/IT8547624A0/it
Application granted granted Critical
Publication of IT1217303B publication Critical patent/IT1217303B/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/107—Vibrio
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/28—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Vibrionaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/848—Escherichia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IT8547624A 1984-02-01 1985-01-31 Ceppi batterici particolarmente utili per la produzione di vaccini per il trattamenmto di malattie intestinali e simili e metodo di ingegneria gentica per la produzione dei detti vaccini IT1217303B (it)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPG342384 1984-02-01
AUPG795884 1984-11-02

Publications (2)

Publication Number Publication Date
IT8547624A0 true IT8547624A0 (it) 1985-01-31
IT1217303B IT1217303B (it) 1990-03-22

Family

ID=25642755

Family Applications (1)

Application Number Title Priority Date Filing Date
IT8547624A IT1217303B (it) 1984-02-01 1985-01-31 Ceppi batterici particolarmente utili per la produzione di vaccini per il trattamenmto di malattie intestinali e simili e metodo di ingegneria gentica per la produzione dei detti vaccini

Country Status (6)

Country Link
US (1) US5066596A (it)
EP (1) EP0175699A4 (it)
AU (1) AU589114B2 (it)
DK (1) DK442185A (it)
IT (1) IT1217303B (it)
WO (1) WO1985003521A1 (it)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL79432A (en) * 1985-07-31 1992-05-25 Univ Leland Stanford Junior Unicellular microorganisms having invasive capability due to exogenous inv gene and vaccines comprising such microorganisms
EP0251579A3 (en) * 1986-06-24 1989-03-22 Enterovax Research Pty. Ltd. Non-antibiotic marker system
EP0257837A1 (en) * 1986-08-19 1988-03-02 Enterovax Research Pty. Ltd. Hybrid bacterial strain
US5124153A (en) * 1987-08-24 1992-06-23 University Of Tennessee Research Corp. Therapeutic compositions against streptococcal infections, transformed hosts, methods of immunization and genetically engineered products
US5162226A (en) * 1987-08-24 1992-11-10 University Of Tennessee Research Corp. (U.T.R.C.) Therapeutic compositions against streptococcal infections, transformed hosts, methods of immunization and genetically engineered products
EP0381706B1 (en) * 1987-10-07 1995-04-26 Washington University A method of maintaining a desired recombinant gene in a genetic population of cells
JPH03501326A (ja) * 1988-06-20 1991-03-28 ルミニス・プロプライアタリー・リミテッド 血清型分類用ｄｎａプローブ
JPH0284172A (ja) * 1988-07-21 1990-03-26 Smithkline Beckman Corp 異種遺伝子の発現能を有し、組換え型ワクチンとして有用なサルモネラ形質転換体
US6043057A (en) * 1988-09-16 2000-03-28 Vitec Aktiebolag Recombinant systems for expression of the cholera B-sub-unit with the aid of foreign promoters and/or leader peptides
US5149532A (en) * 1989-11-01 1992-09-22 Cedars Sinai Medical Center Method of vaccine or toxoid preparation and immunization by colonization with recombinant microorganisms
DK0556333T3 (da) * 1990-11-09 2003-07-14 Univ Washington Avirulente Salmonella mikrober, der omfatter en mutation i cdt genet, og anvendelser deraf
US5622670A (en) * 1993-05-14 1997-04-22 Rowley; William Process for fabricating crosslinked polyethylene tubing ends
AU2816095A (en) * 1994-06-24 1996-01-19 Children's Hospital Medical Center Escherichia coli o157:h7 epithelial adhesin
GR950300072T1 (en) * 1995-10-13 1996-01-31 Schweiz Serum & Impfinst Recombinant live vaccines against Gram-negative enteric pathogens
US6344201B1 (en) 1998-03-31 2002-02-05 Anthony T. Maurelli Methods of identifying bacterial genes that are incompatible with bacterial pathogenicity, and the use of such genes, such as cadA, to reduce pathogenicity in a bacteria or to combat pathogenic bacterial infections
US20030194798A1 (en) 2001-05-24 2003-10-16 Surber Mark W. Minicell compositions and methods
US7396822B2 (en) * 2001-05-24 2008-07-08 Vaxiion Therapeutics, Inc. Immunogenic minicells and methods of use
GB0212666D0 (en) 2002-05-31 2002-07-10 Secr Defence Immunogenic sequences
EP1670505B1 (en) * 2003-09-18 2012-11-14 GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Dna promoters and anthrax vaccines
WO2006055024A2 (en) * 2004-04-05 2006-05-26 Vaxiion Therapeutics, Inc. Minicells as vaccines
WO2007028985A2 (en) * 2005-09-07 2007-03-15 The Secretary Of State For Defence Adjuvanted vaccine
WO2008012538A2 (en) 2006-07-25 2008-01-31 The Secretary Of State For Defence Live vaccine strains of francisella
GB0906234D0 (en) 2009-04-14 2009-05-20 Secr Defence Vaccine
US8709444B2 (en) 2009-05-14 2014-04-29 Northwestern University Live-attenuated compositions for bacterial infections
DK2675474T3 (en) 2011-02-15 2019-04-23 Vaxiion Therapeutics Llc THERAPEUTIC COMPOSITIONS AND PROCEDURES FOR TARGETED ADMINISTRATION OF BIOACTIVE MOLECULES BY BACK-TERIAL MINICLES BASED ON ANTIBODY AND FC-CONTAINING TAR-GETING MOLECULES
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB209314A (en) * 1923-02-07 1924-01-10 Francis John Cheadle A new or improved horse shoe
US3856935A (en) * 1971-04-29 1974-12-24 Schweiz Serum & Impfinst Oral typhoid vaccine and method of preparing the same
GB1472624A (en) * 1974-09-02 1977-05-04 Canadian Patents Dev Enteric disease vaccine
US4264737A (en) * 1978-09-21 1981-04-28 President And Fellows Of Harvard College Method of making genetically stable mutants of vibrio cholerae
US4328209A (en) * 1979-04-11 1982-05-04 Board Of Regents, The University Of Texas System Cholera vaccine
US4311797A (en) * 1979-09-18 1982-01-19 University Of Saskatchewan Anucleated live E. coli vaccine
IL59663A (en) * 1980-03-19 1983-02-23 Univ Ramot Vaccines obtained from bacterial mutant strains of enterobacteriaceae and pseudomonaceae
GB2094314A (en) * 1981-02-05 1982-09-15 Wellcome Found Recombinant DNA
NZ199866A (en) * 1981-03-09 1984-11-09 Cetus Corp Vaccine for prevention of gastroenteric disease:non-pathogenic strain genetically engineered to comprise genes for adhesin and/or toxoids
US4632830A (en) * 1981-07-31 1986-12-30 The United States Of America As Represented By The Secretary Of The Army Oral vaccine for immunization against enteric disease
CA1338705C (en) * 1981-10-22 1996-11-12 Roy Curtiss Iii Vaccines obtained from antigenic gene products of recombinant genes
WO1983002456A2 (en) * 1982-01-18 1983-07-21 Ceska, Miroslav New plasmids and bacterial strains and production process thereo f
JPS58146596A (ja) * 1982-02-25 1983-09-01 Takeda Chem Ind Ltd 組換えｄｎａ、それで形質転換させた微生物およびそれらの用途
US4440748A (en) * 1982-04-03 1984-04-03 Merck & Co., Inc. Strain of Escherichia coli by bacterial conjugation
US4666837A (en) * 1982-05-24 1987-05-19 Smithkline-Rit DNA sequences, recombinant DNA molecules and processes for producing the A and B subunits of cholera toxin and preparations containing so-obtained subunit or subunits
GB8314645D0 (en) * 1983-05-26 1983-06-29 Wellcome Found Bivalent vaccines

Also Published As

Publication number Publication date
EP0175699A4 (en) 1988-06-13
AU3890085A (en) 1985-08-27
DK442185D0 (da) 1985-09-30
EP0175699A1 (en) 1986-04-02
WO1985003521A1 (en) 1985-08-15
DK442185A (da) 1985-11-29
US5066596A (en) 1991-11-19
IT1217303B (it) 1990-03-22
AU589114B2 (en) 1989-10-05

Similar Documents

Publication Publication Date Title
IT8547624A0 (it) Ceppi batterici particolarmente utili per la produzione di vaccini per il trattamento di malattie intestinali e simili e metodo di ingegneria genetica per la produzione dei detti vaccini
IT1223709B (it) Anelli terapeutici e procedimento per la loro produzione
KR860004663A (ko) 판의 단면 형상 제어식 압연방법 및 압연기
IT1219084B (it) Procedimento per la fabbricazione di cemento
IT1156487B (it) Procedimento e microrganismi per la produzione della l lisina mediante fermentazione
KR900700196A (ko) 고규소 강판의 온간압연 방법
NO180181C (no) Fremgangsmåte for fremstilling av et is-kjernedannende protein, plasmider og bakteriestammer
IT1190177B (it) Metodo per la produzione di materiali-fibrosi-non tessuti,elasticizzati e relativi prodotti
AU2659088A (en) Method for the treatment of anxiety
IT8012679A0 (it) Metodo per la produzione di cemento ed impianto per l attuazione di tale metodo
FI885914A (fi) Kokolihasta muotoiltujen tuotteiden valmistusmenetelmä
IT8609432A0 (it) Metodo per la produzione di sbarramenti di contenimento di contaminati e simili.
PT87332A (pt) Method of purification of product of expression of recombinant ferment
FI99144B (fi) Menetelmä Plasmodium falciparum -proteiinien valmistamiseksi geeniteknisesti ja siinä käyttökelpoisia tuotteita
NZ216723A (en) Production of insecticidal protein by genetic engineering methods
EP0299295A3 (en) Polyglycerol esters of lanolin acids, method for their production and their application as emulsifiers
IT1217825B (it) Procedimento ed impianto per la coltura di microorganismi
IT8748059A0 (it) Procedimento per la produzione di etanolo mediante ceppi di microorganismo ad elevata resistenza
IT8621735A1 (it) Microorganismi manipolati con mezzi di ingegneria genetica per la produzione di l-amminoacidi
IT8522982A0 (it) Vettori di espressione e metodo per la loro produzione.
IT8940030A0 (it) Procedimento ed impianto per la produzione di prodotti ceramici smaltati quali piastrelle e simili
FR2559997B1 (fr) Procede technique de la culture de la truffe
IT8719490A0 (it) Procedimento per la produzione continua di isoftalodinitrile.
IT8720559A0 (it) Metodo per la produzione in scala industriale di pasta alimentare fresca e impianto per l'attuazione di tale metodo.
IT8222835A0 (it) Isoneri di amminoacidi eprocedimento per la loro produzione.